{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:48:49Z","timestamp":1779166129321,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cyto.2023.156311","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:39:43Z","timestamp":1690850383000},"page":"156311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A meta analysis on the utility of Anakinra in severe COVID-19 disease"],"prefix":"10.1016","volume":"169","author":[{"given":"Aliae A.R.","family":"Mohamed Hussein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Sayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Abdelshafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam Abdelaal","family":"Hammam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Kedwany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrouk Alaa-eldein","family":"Elkholy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam H.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10223","key":"10.1016\/j.cyto.2023.156311_b0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cyto.2023.156311_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/17476348.2020.1816831","article-title":"Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons","volume":"15","author":"Nathan","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.cyto.2023.156311_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108588","article-title":"SARS-CoV-2 infections in children and young people","volume":"220","author":"Felsenstein","year":"2020","journal-title":"Clin. Immunol."},{"issue":"10239","key":"10.1016\/j.cyto.2023.156311_b0020","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","article-title":"Cytokine Storms: Understanding COVID-19","volume":"53","author":"Mangalmurti","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cyto.2023.156311_b0030","first-page":"e358","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"LancetRheumatol."},{"issue":"10229","key":"10.1016\/j.cyto.2023.156311_b0035","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2023.156311_b0040","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"1446","author":"Ragab","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156311_b0045","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review","volume":"36","author":"Mertens","year":"2009","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156311_b0050","first-page":"209","article-title":"Interleukin-1 receptor antagonist in the treatment of COVID-19 induced cytokine storm","volume":"5","author":"Moradi","year":"2020","journal-title":"Journal of Cellular & Molecular Anesthesia."},{"key":"10.1016\/j.cyto.2023.156311_b0055","article-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019","journal-title":"John Wiley & Sons"},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.cyto.2023.156311_b0065","first-page":"205","author":"Higgins","year":"2019","journal-title":"Assessing risk of bias in a randomized trial. Cochrane handbook for systematic reviews of interventions."},{"key":"10.1016\/j.cyto.2023.156311_b0070","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000."},{"issue":"4","key":"10.1016\/j.cyto.2023.156311_b0075","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jiph.2020.12.034","article-title":"SARS-CoV-2 infection in children, clinical characteristics, diagnostic findings and therapeutic interventions at a tertiary care center in Riyadh, Saudi Arabia","volume":"14","author":"Alharbi","year":"2021","journal-title":"J. Infect. Public Health"},{"issue":"4","key":"10.1016\/j.cyto.2023.156311_b0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11739-020-02600-z","article-title":"Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study","volume":"16","author":"Aomar-Mill\u00e1n","year":"2021","journal-title":"Intern. Emerg. Med."},{"issue":"10","key":"10.1016\/j.cyto.2023.156311_b0085","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with Anakinra in moderate to severe COVID-19 pneumonia: case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2023.156311_b0090","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijid.2020.11.149","article-title":"Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study","volume":"103","author":"Balkhair","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cyto.2023.156311_b0095","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.ijid.2021.03.031","article-title":"The effect of tocilizumab, Anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: a prospective cohort study with multivariate analysis of factors affecting the antibody response","volume":"105","author":"Ba\u015faran","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11481-020-09966-z","article-title":"Can cytokine blocking prevent depression in COVID-19 survivors?","volume":"16","author":"Benedetti","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.cyto.2023.156311_b0105","article-title":"Timely recognition and early multi-step antinflammatory therapy may prevent ICU admission of patients with MIS-C: Proposal for a severity score. Frontiers","volume":"9","author":"Brisca","year":"2021","journal-title":"Pediatrics"},{"issue":"32","key":"10.1016\/j.cyto.2023.156311_b0110","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.cyto.2023.156311_b0115","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose Anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"The Lancet Rheumatology."},{"issue":"4","key":"10.1016\/j.cyto.2023.156311_b0120","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study","volume":"3","author":"Cavalli","year":"2021","journal-title":"The Lancet Rheumatology."},{"issue":"2","key":"10.1016\/j.cyto.2023.156311_b0125","first-page":"e381","article-title":"Role of Biological Agents in the Treatment of SARS-CoV-2\u2013Associated Multisystem Inflammatory Syndrome in Children","volume":"28","author":"\u00c7elikel","year":"2022","journal-title":"JCR: J. Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156311_b0130","first-page":"rkaa040","article-title":"Safety of intravenous Anakinra in COVID-19 with evidence of hyperinflammation, a case series. Rheumatology Advances","volume":"4","author":"Clark","year":"2020","journal-title":"Practice"},{"issue":"2","key":"10.1016\/j.cyto.2023.156311_b0135","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1111\/bjh.16873","article-title":"IL-1 blockade with Anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement","volume":"190","author":"Day","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cyto.2023.156311_b0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijid.2021.02.041","article-title":"Effectiveness of Anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study","volume":"105","author":"de la Calle","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.cyto.2023.156311_b0145","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial","volume":"9","author":"Declercq","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cyto.2023.156311_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.675678","article-title":"Respiratory impairment predicts response to IL-1 and IL-6 blockade in COVID-19 patients with severe pneumonia and hyper-inflammation","volume":"12","author":"Della-Torre","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2023.156311_b0155","doi-asserted-by":"crossref","unstructured":"Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Komnos A, Mouktaroudi M, et al. Favorable Anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host & Microbe. 2020;28(1):117-23. e1.","DOI":"10.1016\/j.chom.2020.05.007"},{"issue":"3","key":"10.1016\/j.cyto.2023.156311_b0160","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/jmv.26473","article-title":"Evaluation of 17 patients with COVID-19 pneumonia treated with Anakinra according to HScore, SOFA, MuLBSTA, and Brescia-COVID respiratory severity scale (BCRSS) scoring systems","volume":"93","author":"Erden","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cyto.2023.156311_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.594127","article-title":"Case report: case series of children with multisystem inflammatory syndrome following SARS-CoV-2 infection in Switzerland","volume":"8","author":"Fouriki","year":"2021","journal-title":"Front. Pediatr."},{"issue":"7","key":"10.1016\/j.cyto.2023.156311_b0170","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.4049\/jimmunol.2001126","article-title":"IL-1 receptor antagonist Anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study","volume":"206","author":"Franzetti","year":"2021","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.cyto.2023.156311_b0175","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.3390\/jcm10174019","article-title":"Anakinra versus baricitinib: different strategies for patients hospitalized with COVID-19","volume":"10","author":"Garc\u00eda-Garc\u00eda","year":"2021","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.cyto.2023.156311_b0180","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"The Lancet Rheumatology."},{"key":"10.1016\/j.cyto.2023.156311_b0185","doi-asserted-by":"crossref","unstructured":"Iglesias-Juli\u00e1n E, L\u00f3pez-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-L\u00f3pez PD, Colazo-Burlato M, et al. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. Journal of autoimmunity. 2020;115:102537.","DOI":"10.1016\/j.jaut.2020.102537"},{"issue":"3","key":"10.1016\/j.cyto.2023.156311_b0190","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000519090","article-title":"ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients","volume":"14","author":"Karakike","year":"2022","journal-title":"J. Innate Immun."},{"issue":"2","key":"10.1016\/j.cyto.2023.156311_b0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/iid3.563","article-title":"A randomized controlled clinical trial on efficacy and safety of Anakinra in patients with severe COVID-19","volume":"10","author":"Kharazmi","year":"2022","journal-title":"Immun. Inflammation Dis."},{"issue":"9","key":"10.1016\/j.cyto.2023.156311_b0200","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/03630242.2021.1981517","article-title":"Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe COVID-19?","volume":"61","author":"Karaka\u015f","year":"2021","journal-title":"Women Health"},{"key":"10.1016\/j.cyto.2023.156311_b0205","doi-asserted-by":"crossref","unstructured":"Khatri A, Malhotra P, Izard S, Kim A, Oppenheim M, Gautam-Goyal P, et al., editors. Hospital-acquired bloodstream infections in patients hospitalized with severe acute respiratory syndrome coronavirus 2 infection (coronavirus disease 2019): association with immunosuppressive therapies. Open forum infectious diseases; 2021: Oxford University Press US.","DOI":"10.1093\/ofid\/ofab339"},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03364-w","article-title":"Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study","volume":"24","author":"Kooistra","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.cyto.2023.156311_b0215","doi-asserted-by":"crossref","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of Anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.cyto.2023.156311_b0220","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with Anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2023.156311_b0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijid.2020.07.081","article-title":"Early identification of COVID-19 cytokine storm and treatment with Anakinra or tocilizumab","volume":"99","author":"Langer-Gould","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cyto.2023.156311_b0230","article-title":"MIS-C treatment: is IVIG always necessary? Frontiers","volume":"1202","author":"Licciardi","year":"2021","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.cyto.2023.156311_b0235","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of Anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","author":"Tharaux","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-021-03548-y","article-title":"Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment","volume":"25","author":"Mastrolia","year":"2021","journal-title":"Crit. Care"},{"key":"10.1016\/j.cyto.2023.156311_b0245","first-page":"891","article-title":"Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients","author":"Monti","year":"2021","journal-title":"Minerva anestesiol."},{"issue":"10","key":"10.1016\/j.cyto.2023.156311_b0250","article-title":"Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report. European Journal of Case Reports","volume":"8","author":"Nan","year":"2021","journal-title":"Intern. Med."},{"issue":"3","key":"10.1016\/j.cyto.2023.156311_b0255","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.chest.2020.09.275","article-title":"Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm","volume":"159","author":"Narain","year":"2021","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.cyto.2023.156311_b0260","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/art.41422","article-title":"Use of Anakinra to prevent mechanical ventilation in severe COVID-19: a case series","volume":"72","author":"Navarro-Mill\u00e1n","year":"2020","journal-title":"Arthritis & Rheumatology."},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0265","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.05.002","article-title":"Safety and efficacy of early high-dose IV Anakinra in severe COVID-19 lung disease","volume":"146","author":"Pontali","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2023.156311_b0270","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2021.01.024","article-title":"Efficacy of early anti-inflammatory treatment with high doses of intravenous Anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia","volume":"147","author":"Pontali","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jpc.15674","article-title":"Multisystem inflammatory syndrome in children during severe acute respiratory syndrome coronavirus-2 pandemic in Turkey: A single-centre experience","volume":"58","author":"Savas Sen","year":"2022","journal-title":"J. Paediatr. Child Health"},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-021-00658-3","article-title":"A descriptive study on multisystem inflammatory syndrome in children in a single center in West Michigan","volume":"19","author":"Shabab","year":"2021","journal-title":"Pediatr. Rheumatol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156311_b0285","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/00325481.2021.1987732","article-title":"The clinical course and short-term health outcomes of multisystem inflammatory syndrome in children in the single pediatric rheumatology center","volume":"133","author":"S\u00f6zeri","year":"2021","journal-title":"Postgrad. Med."},{"issue":"12","key":"10.1016\/j.cyto.2023.156311_b0290","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1007\/s00277-020-04160-w","article-title":"IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection","volume":"99","author":"Villegas","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cyto.2023.156311_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: Immunology and treatment options","volume":"215","author":"Felsenstein","year":"2020","journal-title":"Clin. Immunol."},{"issue":"12","key":"10.1016\/j.cyto.2023.156311_b0300","doi-asserted-by":"crossref","first-page":"e1003501","DOI":"10.1371\/journal.pmed.1003501","article-title":"Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis","volume":"17","author":"Kim","year":"2020","journal-title":"PLoS Med."},{"issue":"12","key":"10.1016\/j.cyto.2023.156311_b0305","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1093\/rheumatology\/keab447","article-title":"Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis","volume":"60","author":"Barkas","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2023.156311_b0310","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2021.01.016","article-title":"Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies","volume":"86","author":"Pasin","year":"2021","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0315","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.41469","article-title":"Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis","volume":"73","author":"Putman","year":"2021","journal-title":"Arthritis & Rheumatology."},{"key":"10.1016\/j.cyto.2023.156311_b0320","article-title":"Anakinra for rheumatoid arthritis","volume":"1","author":"Mertens","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.cyto.2023.156311_b0325","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.berh.2007.05.006","article-title":"The course of established rheumatoid arthritis","volume":"21","author":"Scott","year":"2007","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2023.156311_b0330","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.624248","article-title":"Case report: use of Anakinra in multisystem inflammatory syndrome during COVID-19 pandemic","volume":"8","author":"Della Paolera","year":"2021","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.cyto.2023.156311_b0335","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and Anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.cyto.2023.156311_b0340","doi-asserted-by":"crossref","first-page":"e24434","DOI":"10.1002\/jcla.24434","article-title":"Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis","volume":"36","author":"Naveed","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"issue":"22","key":"10.1016\/j.cyto.2023.156311_b0345","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.3390\/jcm10225366","article-title":"Immunomodulation and reduction of thromboembolic risk in hospitalized COVID-19 patients: systematic review and meta-analysis of randomized trials","volume":"10","author":"Sagris","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cyto.2023.156311_b0350","first-page":"85","article-title":"Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications","volume":"1","author":"Potere","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:55:39Z","timestamp":1760910939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623001898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":70,"alternative-id":["S1043466623001898"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156311","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta analysis on the utility of Anakinra in severe COVID-19 disease","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156311"}}